Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: March 2010
-
By Donald Zuhn — On Tuesday, Senator Mary Landrieu (D-LA) introduced legislation (S. 3089) that would require the Office of Advocacy of the Small Business Administration (SBA) to conduct a study and report on the effects of changes to U.S. patent law that would result from enactment of the Patent Reform Act of 2009. …
-
By Donald Zuhn — Last month, the Association of University Technology Managers (AUTM) released its U.S. licensing survey for FY2008. According to a GenomeWeb Daily News report, a majority of the academic and research institutions that answered the survey indicated that they filed more patent applications and were involved in more start-ups during the…
-
By Juan Serrano — Back in 2003, Mexico enacted linkage regulations to avoid the granting of marketing authorizations in violation of patent rights. The system created by these regulations is far less elaborate than the one set forth by the Hatch-Waxman act in the U.S., as there is no extension/term restoration, and there is…
-
By Donald Zuhn — On February 25th, Senate Judiciary Committee Chairman Patrick Leahy (D-VT) announced that the Committee had reached a "tentative agreement in principle" regarding patent reform legislation (see "Chairman Leahy Announces 'Tentative Agreement in Principle' on Patent Reform Bill"). Chairman Leahy noted that the Committee would release details regarding the bill "in…
-
By Kevin E. Noonan — Policy arguments based solely on outcome rather than process are rarely effective when put into practice. This is because the desired benefits of the outcome blind the policymaker to the question of whether the desired outcome can be achieved without considering the effects (intended or otherwise) by the process. …
-
By Sarah Fendrick — In order to assess the burden of patent-related paperwork, the U.S. Patent and Trademark Office has retained ICF International (ICF) to conduct an independent study. As described in a notice in the Federal Regster (75 Fed. Reg. 8649), the overall objectives of the study included: (1) Develop an independent, publicly…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Schering Corp. et al. v. Teva Pharmaceuticals USA, Inc. et al.2:10-cv-01058; filed March 2, 2010 in the District Court of New Jersey • Plaintiffs: Schering Corp.; MSP Singapore Co. LLC• Defendants: Teva Pharmaceuticals USA,…
-
By James DeGiulio — On February 9th, Athersys, Inc. was issued U.S. Patent No. 7,659,118 covering multipotent adult stem cells (MASC), their isolation and expansion, and related pharmaceutical compositions. In a February 10, 2010 press release, the Cleveland-based company also announced the grant of European patent EP 1 218 489 B1, the counterpart to…
-
By Sarah Fendrick — Last month, the U.S. Patent and Trademark Office released the first issue of inventorseye. Inventorseye is a bimonthly publication released by the USPTO in an effort to provide the necessary resources for an independent inventor. The electronic publication provides information on events, organizations, and meetings of interest to the independent…
-
March 9, 2010 – "Patent Infringement Claims, Opinions of Counsel and Attorney-Client Privilege: Best Practices for Opinion Letters after Seagate and Qualcomm" (Technology Transfer Tactics & Strafford) – 1:00 – 2:30 PM (EST) March 17-18, 2010 – 18th Forum on Biotech Patenting (C5) – Munich, Germany March 18-19, 2010 – 4th Summit on Biosimilars and…
Patent Docs 